[{"id":"3a138d15-6bca-4eff-8361-765e025c0dc8","acronym":"FORTITUDE-101","url":"https://clinicaltrials.gov/study/NCT05052801","created_at":"2021-09-22T11:53:35.151Z","updated_at":"2025-02-25T16:38:37.071Z","phase":"Phase 3","brief_title":"Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","source_id_and_acronym":"NCT05052801 - FORTITUDE-101","lead_sponsor":"Amgen","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 547","initiation":"Initiation: 03/07/2022","start_date":" 03/07/2022","primary_txt":" Primary completion: 08/18/2025","primary_completion_date":" 08/18/2025","study_txt":" Completion: 08/18/2025","study_completion_date":" 08/18/2025","last_update_posted":"2025-02-07"},{"id":"e79a541e-0cd8-480b-90cf-f790043b9fc7","acronym":"FORTITUDE-102","url":"https://clinicaltrials.gov/study/NCT05111626","created_at":"2021-11-08T14:53:12.581Z","updated_at":"2024-07-02T16:34:59.979Z","phase":"Phase 3","brief_title":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT05111626 - FORTITUDE-102","lead_sponsor":"Amgen","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Recruiting","enrollment":" Enrollment 528","initiation":"Initiation: 03/14/2022","start_date":" 03/14/2022","primary_txt":" Primary completion: 09/26/2026","primary_completion_date":" 09/26/2026","study_txt":" Completion: 09/26/2026","study_completion_date":" 09/26/2026","last_update_posted":"2024-05-30"},{"id":"7bdf22c5-b0e5-4dd7-ba06-b849bce2df96","acronym":"FORTITUDE-201","url":"https://clinicaltrials.gov/study/NCT05267470","created_at":"2022-03-04T15:53:35.624Z","updated_at":"2024-07-02T16:35:04.416Z","phase":"Phase 1","brief_title":"A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)","source_id_and_acronym":"NCT05267470 - FORTITUDE-201","lead_sponsor":"Amgen","biomarkers":" KRAS • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression","tags":["KRAS • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • bemarituzumab (AMG 552)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 04/09/2024","primary_completion_date":" 04/09/2024","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2024-05-10"},{"id":"94fc3ab5-0532-4f36-b807-3064b8e380bd","acronym":"FIGHT","url":"https://clinicaltrials.gov/study/NCT03694522","created_at":"2021-01-17T17:12:46.809Z","updated_at":"2024-07-02T16:35:17.364Z","phase":"Phase 2","brief_title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT03694522 - FIGHT","lead_sponsor":"Five Prime Therapeutics, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Completed","enrollment":" Enrollment 155","initiation":"Initiation: 09/14/2018","start_date":" 09/14/2018","primary_txt":" Primary completion: 09/23/2020","primary_completion_date":" 09/23/2020","study_txt":" Completion: 05/13/2022","study_completion_date":" 05/13/2022","last_update_posted":"2024-02-28"},{"id":"79f91b60-669d-47f6-83fb-b95eccd77343","acronym":"NIVOFGFR2","url":"https://clinicaltrials.gov/study/NCT05859477","created_at":"2023-05-16T17:06:20.563Z","updated_at":"2024-07-02T16:35:24.858Z","phase":"Phase 2","brief_title":"Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer","source_id_and_acronym":"NCT05859477 - NIVOFGFR2","lead_sponsor":"Kidney Cancer Research Bureau","biomarkers":" HER-2 • PD-L1 • FGFR2","pipe":" | ","alterations":" HER-2 negative • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression","tags":["HER-2 • PD-L1 • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 06/05/2022","start_date":" 06/05/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-01"},{"id":"d4d894ac-2658-4499-8ad7-5be03852e67a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173142","created_at":"2021-12-29T13:53:45.797Z","updated_at":"2025-02-25T14:52:10.343Z","phase":"Phase 1/2","brief_title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","source_id_and_acronym":"NCT05173142","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":" | ","alterations":" PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 01/22/2022","start_date":" 01/22/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-03-08"},{"id":"5ac6cf9e-efcf-436f-8803-ff8e9e904ab6","acronym":"RPT835GC1B","url":"https://clinicaltrials.gov/study/NCT04071184","created_at":"2021-01-18T19:55:52.106Z","updated_at":"2024-07-02T16:36:55.182Z","phase":"Phase 1b","brief_title":"Study of Alofanib in Patients With Metastatic Gastric Cancer","source_id_and_acronym":"NCT04071184 - RPT835GC1B","lead_sponsor":"Russian Pharmaceutical Technologies","biomarkers":" FGFR2 • FRS2","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression","tags":["FGFR2 • FRS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alofanib (RPT835)"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 05/26/2019","start_date":" 05/26/2019","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2019-09-26"}]